Table 4.
Summary of univariate analysis of OS rate
| Factor | 1-yr OS rate (%) | p-value |
|---|---|---|
| Time from primary surgery to recurrence (mo) | 0.0003 | |
| ≤6 | 50.0 | |
| >6 | 87.9 | |
| Site of recurrence | 0.2309 | |
| Axial | 77.1 | |
| Anterior | 66.7 | |
| Posterior | 85.6 | |
| Lateral | 100 | |
| Presence of distant metastasis | 0.049 | |
| No | 89.2 | |
| Yes | 71.3 | |
| Serum CEA (ng/mL) | 0.9336 | |
| ≥5.0 | 83.7 | |
| <5.0 | 75.0 | |
| Recurrence tumor size (cm) | 0.3298 | |
| <4.0 | 79.3 | |
| ≥4.0 | 86.2 | |
| BED (Gy10) | 0.0730 | |
| ≥75 | 100 | |
| <75 | 77.9 | |
| Concurrent chemotherapy | 0.6065 | |
| Yes | 84.4 | |
| No | 80.0 | |
| Adjuvant chemotherapy | 0.8559 | |
| Yes | 82.6 | |
| No | 75.0 |
OS, overall survival; CEA, carcinoembryonic antigen; BED, biological effective dose with α/β = 10 Gy.